These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2703739)

  • 21. Histopathological study of apparently normal skin of patients with leprosy.
    El-Darouti MA; Hussein S; Marzouk SA; Nabil N; Hunter NS; Mahgoub D; El-Eishi NH; Abdel-Halim MR
    Int J Dermatol; 2006 Mar; 45(3):292-6. PubMed ID: 16533232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of low and conventional dosages of dapsone in the treatment of lepromatous leprosy.
    Iyer CG; Balakrishnan S; Ramu G
    Lepr India; 1977 Jul; 49(3):372-86. PubMed ID: 592740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of leprosy disabilities in Gorakhpur (Uttar Pradesh).
    Girdhar M; Arora SK; Mohan L; Mukhija RD
    Indian J Lepr; 1989 Oct; 61(4):503-13. PubMed ID: 2533603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy.
    Jamet P; Blanc L; Fayne OC; Traore I; Bobin P
    Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):209-14. PubMed ID: 8046259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability of dapsone on oral administration of Dapsomine--a comparative evaluation.
    Venkatesan K; Chauhan SL; Girdhar A; Girdhar BK
    Indian J Lepr; 1993; 65(2):157-61. PubMed ID: 8345229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Borderline tuberculoid leprosy developing in a pure neuritic case.
    Porichha D; Mahapatra DC
    Indian J Lepr; 1991; 63(2):235-7. PubMed ID: 1783794
    [No Abstract]   [Full Text] [Related]  

  • 27. Detection of transforming growth factor-beta 1 in dermal lesions of different clinical forms of leprosy.
    Goulart IM; Figueiredo F; Coimbra T; Foss NT
    Am J Pathol; 1996 Mar; 148(3):911-7. PubMed ID: 8774145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline lepromatous leprosy presenting as a single cutaneous plaque.
    Armour KS; Scolyer RA; Barnetson RS
    Australas J Dermatol; 2005 Aug; 46(3):181-3. PubMed ID: 16008652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 open trial of pentoxifylline for the treatment of leprosy reactions.
    Dawlah ZM; Cabrera A; Ahern K; Levis WR
    Int J Lepr Other Mycobact Dis; 2002 Mar; 70(1):38-43. PubMed ID: 12120041
    [No Abstract]   [Full Text] [Related]  

  • 30. Serious side effects of rifampin on the course of WHO/MDT: a case report.
    Namisato M; Ogawa H
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):277-82. PubMed ID: 11221090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients.
    Gallo ME; Alvim MF; Nery JA; Albuquerque EC; Sarno EN
    Indian J Lepr; 1996; 68(3):235-45. PubMed ID: 8889609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapsone induced acute photosensitivity dermatitis; a case report and review of literature.
    De D; Dogra S; Kaur I
    Lepr Rev; 2007 Dec; 78(4):401-4. PubMed ID: 18309716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term prothionamide compliance: a study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid.
    Ellard GA; Kiran KU; Stanley JN
    Lepr Rev; 1988 Jun; 59(2):163-75. PubMed ID: 3246926
    [No Abstract]   [Full Text] [Related]  

  • 34. Hematological alterations in lepromatous leprosy: A cross-sectional observational study.
    Gupta B; Gupta S; Chaudhary M; Raj AT; Awan KH; Patil S
    Dis Mon; 2020 Jul; 66(7):100919. PubMed ID: 31796205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse of paucibacillary leprosy after short course multidrug therapy.
    Pavithran K
    Indian J Lepr; 1988 Apr; 60(2):225-9. PubMed ID: 3192971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramuscular injection of dapsone in therapy for leprosy: a new approach.
    Modderman ES; Huikeshoven H; Zuidema J; Leiker DL; Merkus FW
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):51-6. PubMed ID: 7061179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence and management of leprosy reaction in China in 2005.
    Shen J; Liu M; Zhou M; Wengzhong L
    Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Borderline-tuberculoid relapse in lepromatous leprosy.
    Girdhar BK; Girdhar A; Chauhan SL; Malaviya GN; Husain S; Mukherjee A
    Lepr Rev; 1993 Jun; 64(2):157-63. PubMed ID: 8341119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response of leprosy patients with single lesions to MDT.
    Katoch K; Natrajan M; Yadav VS; Bhatia AS
    Acta Leprol; 1995; 9(3):133-7. PubMed ID: 7631584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.